BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Helsinn Therapeutics (US) Inc. 

1160 US Highway 22
Suite 104
Bridgewater  New Jersey  08807  U.S.A.
Phone: 908-203-6549 Fax: 908-231-1459


SEARCH JOBS



Helsinn is a privately owned, self-financing pharmaceutical group with headquarters in Lugano, Switzerland and subsidiaries in Ireland and the USA. The Helsinn Group has been built on the basis of a licensing of pharmaceuticals, with the recent addition of medical devices in therapeutic niche areas. Helsinn is an important player in Cancer Supportive Care and sells its products through unique business model that is focused on the in- and out- distributors in 87 countries worldwide.

Helsinn Therapeutics (U.S.), Inc. was established in January, 2009 and is currently developing clinical and preclinical stage ghrelin receptor agonists and antagonists in cancer and gastrointestinal supportive care. The company’s vision is to become a leading specialty company focused on supportive care with direct sales in the U.S. market.


 Key Statistics


Email:
Ownership: Subsidiary

Web Site: Helsinn Therapeutics (US) Inc.
Employees: 40
Symbol: 
 



Industry
Pharmaceutical






 Company News
Helsinn Release: Data Presented At The International Society Of Paediatric Oncology (SIOP) Congress Show Palonosetron Is A Valuable Option For Treating Pediatric Patients Receiving Moderately To Highly Emetogenic Chemotherapy 10/23/2014 12:48:09 PM
Helsinn Therapeutics (US) Inc. Strengthens Its Board Of Directors 6/25/2014 8:23:28 AM
Helsinn Therapeutics (US) Inc. Initiates Extension Study in Late-Stage Anamorelin Clinical Program for Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia 12/7/2011 10:42:46 AM
Helsinn Therapeutics (US) Inc. Initiates Global Pivotal Phase III Clinical Program to Evaluate Anamorelin in Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia 8/23/2011 9:30:40 AM
Helsinn Therapeutics (US) Inc. Anounces New CEO, William Mann 9/9/2009 7:10:02 AM
Helsinn Healthcare SA Announces the Acquisition of Sapphire Therapeutics, Inc. to Establish Helsinn Therapeutics (US) Inc. 1/28/2009 11:27:12 AM